Skip to content 
“Over 300 million yuan!”
Recently, Yaotang Biology, an enterprise in the new district, announced that it has completed a B-round financing of over 300 million yuan. This round of financing was led by Astrazeneca CICC Healthcare Industry Fund, with participation from several well-known investment institutions. So far, the company’s cumulative financing amount has exceeded 575 million yuan.
Not only Yaotang Biology has made new progress and breakthroughs in the field of gene and cell therapy recently, but also many other enterprises in the new district have achieved continuous good news
The 1.3 billion yuan financing has a strong “money-attracting power”
Entering the GMP production base of Yaotang Biology, the staff are busy. After undergoing strict procedures such as inspection and packaging, each clinical drug will be transported to all parts of the world.
These clinical drugs are the innovative in vivo gene-editing drugs developed by Yaotang Biotech. If we imagine a person’s genes as an encyclopedia, gene editing in the body is like precisely finding a letter (the disease-causing gene) in the encyclopedia and editing it. Especially for genetic diseases, it can achieve both symptomatic and root treatment.
In this highly technological field, there are currently no more than 10 enterprises worldwide engaged in the research and development of in vivo gene-editing drugs. Among them, Yaotang Biotech is the first in China and also the company with the most clinical pipelines in the world. It has already had four in vivo gene editing drug pipelines “enter” the clinical stage.
Our independently developed YOLT-101 is the first in vivo base editing therapy in China to have received clinical trial applications approved in both China and the United States. Dr. Wu Yuxuan, the founder of Yaotang Biology, introduced that this drug is used to treat familial hypercholesterolemia. Familial hypercholesterolemia. At present, patients with hyperlipidemia need to take the drugs for a long time. However, YOLT-101 has the potential to achieve “one-time administration, lifelong lipid reduction”, which will bring a brand-new treatment model to patients. It is expected to be launched in about three years.
Write a new answer for the once “unsolvable” disease. Such innovative strength and the speed of clinical transformation have also translated into a remarkable “money-attracting power” – the B-round financing of over 300 million yuan is an acknowledgement from all sides and also a driving force for the enterprise to move forward at a fast pace.
We will continue to adhere to innovation-driven development, focusing on transforming the world’s leading in vivo gene editing technology into innovative drugs that can truly be used for disease treatment, bringing breakthrough changes to more patients. Wu Yuxuan said.
02 Join forces to “group up” and go global
Gene therapy enterprises have secure financing. On the other hand, the cell therapy sector is also writing a new story: Recently, Reindeer Bio and Saiqiao Bio signed a global strategic cooperation agreement, jointly promoting the integrated overseas expansion of the domestic advanced cell therapy drug industry chain.
As a leading enterprise in the field of cell therapy, Reindeer Bio has launched Fokesu, which is the first CAR-T product in China that is fully independently developed and produced throughout the entire process. Since its launch, it has benefited hundreds of multiple myeloma patients in over 10 countries and regions. To enable more patients around the world to benefit as soon as possible, the team has been exploring new models for drug export. This year, it has obtained the first overseas marketing authorization in Macao, China.
In addition to promoting the approval of their products for marketing in more countries and regions, how else can domestic CAR-T innovative drugs “export” themselves?
The “powerful alliance” between Reindeer Bio and Saiqiao Bio this time represents a new path of cooperation. It is reported that Saiqiao Biotechnology is one of the earliest enterprises in China to deeply engage in cell processing and automated equipment. Its high-end equipment can promote the upgrade of cell preparation from traditional manual mode to intelligent mode. Similarly, Reindeer Bio has also accumulated profound experience in drug research and development over the years.
On this basis, both sides will jointly establish a process development mechanism and work together to enhance the “feasibility” of cell therapy product production. In addition, both sides will also integrate each other’s international channel resources to promote the implementation and application of the overall solution in overseas markets.
The two upstream and downstream enterprises join hands and move forward together. This is not only a complementary resource but also a “group going global” in terms of craftsmanship, technology and services. When production is faster and costs are lower, domestic cell therapy drugs are still moving towards a broader stage.
Not only financing and going global, but also many new developments worth mentioning:
The product independently developed by Shihe Gene, the Shihe No.1 ® High-throughput Sequencing Gene Detection Kit for Pan-solid Tumors, has become the world’s first and only high-throughput sequencing large Panel detection product for tumors to simultaneously obtain certifications from the three major international authoritative regulatory agencies, NMPA, FDA, and CE, achieving an outstanding “grand slam” result.
The universal CAR-T product CTD402 of Beiheng Biotech has been recognized by the US FDA as a rare disease in pediatrics for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma…
One good news after another has come in, behind which lies the rapid progress of enterprises and the surging innovation brought about by industrial layout. In the New District’s Biomedical Valley, over 40 cell and gene technology innovation enterprises have gathered, forming a complete industrial chain ranging from gene testing and reagents to mouse gene editing, CAR-T cell therapy, and targeted drugs. As a result, a number of globally and nationally leading products and technologies have emerged and gone global.
The future is worth looking forward to more.
